Key facts
- This page summarizes Mahesh V Patel's Form 4 filing for Lipocine Inc. (LPCN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Jun 2026, 19:31.
Mahesh V Patel - 29 Jun 2026 Form 4 Insider Report for Lipocine Inc. (LPCN)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- LPCN
- Reported as of
- 29 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Jun 2026, 19:31:08 UTC
- Prior SEC filing
- 06 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mahesh V. Patel
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mahesh V Patel filed Form 4 for Lipocine Inc. (LPCN) on 30 Jun 2026.
Change
- Previous filing in this sequence was filed on 06 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001579872
Primary reporting owner
Patel Mahesh V.
- Relationship
- Chief Executive Officer, Director
- Address
- 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY
- Signature
- /s/ Mahesh V. Patel
- Signature date
- 30 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LPCN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +52,781
- Change %
- +30%
- Price
- $2.49*
- Shares after
- 227,214
- Date
- 29 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,781
- Exercise price
- $2.49
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Subject to vesting whereby 1/3 of the shares subject to the award will vest on June 29, 2027 while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years.